相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Sustained treatment-free remission in chronic myeloid leukaemia is associated with an increased frequency of innate CD8(+) T-cells
Emilie Cayssials et al.
BRITISH JOURNAL OF HAEMATOLOGY (2019)
The peripheral differentiation of human natural killer T cells
Jie Liu et al.
IMMUNOLOGY AND CELL BIOLOGY (2019)
Quantitative Difference in PLZF Protein Expression Determines iNKT Lineage Fate and Controls Innate CD8 T Cell Generation
Joo-Young Park et al.
CELL REPORTS (2019)
The tyrosine kinase inhibitor dasatinib acts as a pharmacologic on/off switch for CAR T cells
Katrin Mestermann et al.
SCIENCE TRANSLATIONAL MEDICINE (2019)
Effects of dasatinib on CD8+T, Th1, and Treg cells in patients with chronic myeloid leukemia
Xiaoqing Wei et al.
JOURNAL OF INTERNATIONAL MEDICAL RESEARCH (2019)
Thymic expression of IL-4 and IL-15 after systemic inflammatory or infectious Th1 disease processes induce the acquisition of innate characteristics during CD8+ T cell development
Natalia S. Baez et al.
PLOS PATHOGENS (2019)
NKG2A Down-Regulation by Dasatinib Enhances Natural Killer Cytotoxicity and Accelerates Effective Treatment Responses in Patients With Chronic Myeloid Leukemia
Ming-Chin Chang et al.
FRONTIERS IN IMMUNOLOGY (2019)
Inhibition of SRC family kinases facilitates anti-CTLA4 immunotherapy in head and neck squamous cell carcinoma
Guang-Tao Yu et al.
CELLULAR AND MOLECULAR LIFE SCIENCES (2018)
Unconventional T Cell Targets for Cancer Immunotherapy
Dale I. Godfrey et al.
IMMUNITY (2018)
Regulatory T cell inhibition by dasatinib is associated with natural killer cell differentiation and a favorable molecular response-The final results of the D-first study
Yuho Najima et al.
LEUKEMIA RESEARCH (2018)
Enhanced perforin expression associated with dasatinib therapy in natural killer cells
Noriyoshi Iriyama et al.
LEUKEMIA RESEARCH (2018)
Novel Approaches to Exploiting Invariant NKT Cells in Cancer Immunotherapy
Benjamin J. Wolf et al.
FRONTIERS IN IMMUNOLOGY (2018)
Dasatinib Changes Immune Cell Profiles Concomitant with Reduced Tumor Growth in Several Murine Solid Tumor Models
Can Hekim et al.
CANCER IMMUNOLOGY RESEARCH (2017)
The Hypothesis of the Human inKT/Innate CD8(+) T-Cell Axis Applied to Cancer: Evidence for a Deficiency in Chronic Myeloid Leukemia
Florence Jacomet et al.
FRONTIERS IN IMMUNOLOGY (2017)
Phenotype of NK-Like CD8(+) T Cells with Innate Features in Humans and Their Relevance in Cancer Diseases
Alice Barbarin et al.
FRONTIERS IN IMMUNOLOGY (2017)
The Rho-ROCK pathway as a new pathological mechanism of innate immune subversion in chronic myeloid leukaemia
Sara Basbous et al.
JOURNAL OF PATHOLOGY (2016)
Plasma proteomics in CML patients before and after initiation of tyrosine kinase inhibitor therapy reveals induced Th1 immunity and loss of angiogenic stimuli
Stina Soderlund et al.
LEUKEMIA RESEARCH (2016)
Immunological off-target effects of imatinib
Laurence Zitvogel et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2016)
Evidence for eomesodermin-expressing innate-like CD8+ KIR/NKG2A+ T cells in human adults and cord blood samples
Florence Jacomet et al.
EUROPEAN JOURNAL OF IMMUNOLOGY (2015)
FDA-approved small-molecule kinase inhibitors
Peng Wu et al.
TRENDS IN PHARMACOLOGICAL SCIENCES (2015)
T-bet and Eomes instruct the development of two distinct natural killer cell lineages in the liver and in the bone marrow
Cecile Daussy et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2014)
Dasatinib promotes the potential of proliferation and antitumor responses of human γδT cells in a long-term induction ex vivo environment
K-n Wu et al.
LEUKEMIA (2014)
Cnaracterization of T-bet and Eomes in peripheral human immune cells
James J. Knox et al.
FRONTIERS IN IMMUNOLOGY (2014)
Dasatinib promotes the expansion of a therapeutically superior T-cell repertoire in response to dendritic cell vaccination against melanoma
Devin B. Lowe et al.
ONCOIMMUNOLOGY (2014)
Dasatinib promotes Th1-type responses in granzyme B expressing T-cells
Anna Kreutzman et al.
ONCOIMMUNOLOGY (2014)
Direct effect of dasatinib on proliferation and cytotoxicity of natural killer cells in in vitro study
Takayoshi Uchiyama et al.
HEMATOLOGICAL ONCOLOGY (2013)
Rapid mobilization of cytotoxic lymphocytes induced by dasatinib therapy
S. Mustjoki et al.
LEUKEMIA (2013)
Steady-state production of IL-4 modulates immunity in mouse strains and is determined by lineage diversity of iNKT cells
You Jeong Lee et al.
NATURE IMMUNOLOGY (2013)
Antitumor T-cell responses contribute to the effects of dasatinib on c-KIT mutant murine mastocytoma and are potentiated by anti-OX40
Yan Yang et al.
BLOOD (2012)
Evidence for BCR-ABL-dependent dysfunctions of iNKT cells from chronic myeloid leukemia patients
Alexis Rossignol et al.
EUROPEAN JOURNAL OF IMMUNOLOGY (2012)
Enhancement of natural killer cell effector functions against selected lymphoma and leukemia cell lines by dasatinib
Nicole Hassold et al.
INTERNATIONAL JOURNAL OF CANCER (2012)
Rapid and sustained increase of large granular lymphocytes and rare cytomegalovirus reactivation during dasatinib treatment in chronic myelogenous leukemia patients
Hideo Tanaka et al.
INTERNATIONAL JOURNAL OF HEMATOLOGY (2012)
KLF13 sustains thymic memory-like CD8+ T cells in BALB/c mice by regulating IL-4-generating invariant natural killer T cells
Dazhi Lai et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2011)
T cell receptor signal strength in Treg and iNKT cell development demonstrated by a novel fluorescent reporter mouse
Amy E. Moran et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2011)
Expansion of highly differentiated CD8+ T-cells or NK-cells in patients treated with dasatinib is associated with cytomegalovirus reactivation
A. Kreutzman et al.
LEUKEMIA (2011)
A molecular and functional analysis of large granular lymphocyte expansions in patients with chronic myelogenous leukemia treated with tyrosine kinase inhibitors
John J. Powers et al.
LEUKEMIA & LYMPHOMA (2011)
Dasatinib: A potent SRC inhibitor in clinical development for the treatment of solid tumors
John Araujo et al.
CANCER TREATMENT REVIEWS (2010)
Immunoprofiling of patients with chronic myeloid leukemia at diagnosis and during tyrosine kinase inhibitor therapy
Peter Rohon et al.
EUROPEAN JOURNAL OF HAEMATOLOGY (2010)
The BCR/ABL-inhibitors Imatinib, Nilotinib and Dasatinib differentially affect NK cell reactivity
Julia Salih et al.
INTERNATIONAL JOURNAL OF CANCER (2010)
T cells expressing the transcription factor PLZF regulate the development of memory-like CD8+ T cells
Michael A. Weinreich et al.
NATURE IMMUNOLOGY (2010)
Dasatinib inhibits recombinant viral antigen-specific murine CD4+ and CD8+ T-cell responses and NK-cell cytolytic activity in vitro and in vivo
Cara K. Fraser et al.
EXPERIMENTAL HEMATOLOGY (2009)
Clonal expansion of T/NK-cells during tyrosine kinase inhibitor dasatinib therapy
S. Mustjoki et al.
LEUKEMIA (2009)
The Src/ABL kinase inhibitor dasatinib (BMS-354825) inhibits function of normal human T-lymphocytes in vitro
Stephen Blake et al.
CLINICAL IMMUNOLOGY (2008)
Dasatinib, a small-molecule protein tyrosine kinase inhibitor, inhibits T-cell activation and proliferation
Andrew E. Schade et al.
BLOOD (2008)
Quantitative chemical proteomics reveals mechanisms of action of clinical ABL kinase inhibitors
Marcus Bantscheff et al.
NATURE BIOTECHNOLOGY (2007)
CD1d-restricted NKT cell activation enhanced homeostatic proliferation of CD8+ T cells in a manner dependent on IL-4
Naoko Ueda et al.
INTERNATIONAL IMMUNOLOGY (2006)
分享论文
